Related Experiment Video
Updated: Jul 25, 2026
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 15, 2014
Summary
Itraconazole, a broad-spectrum antifungal, effectively treats systemic fungal infections. Its high tissue affinity means therapy duration depends on clinical cure, not just plasma levels.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Context:
- Itraconazole is a lipophilic triazole antifungal agent.
- It exhibits broad-spectrum activity against various fungal pathogens.
- Effective concentrations are typically around 100 ng/ml.
Purpose:
- To review the clinical utility and pharmacokinetic properties of itraconazole.
- To highlight its efficacy in treating systemic mycoses.
- To inform therapeutic strategies regarding drug absorption and tissue distribution.
Summary:
- Itraconazole demonstrates high tissue affinity, leading to higher concentrations in tissues than plasma.
- Therapy for systemic mycoses requires continuation until clinical and mycological cure.
- Absorption can be reduced in specific patient groups (e.g., transplant recipients, AIDS patients) or with concurrent use of antacids/H2-antagonists, though often not clinically significant.
- Drug interactions include increased cyclosporin A levels and decreased levels with rifampicin, phenytoin, and phenobarbital. Caution is advised with anticoagulants.
Impact:
- Understanding itraconazole's pharmacokinetics is crucial for effective treatment of systemic fungal infections.
- Highlights the importance of clinical and mycological cure for determining therapy duration.
- Provides essential information on drug interactions and absorption variability for safe and effective patient management.
More Related Videos
10:49Identification of Small Molecule-binding Proteins in a Native Cellular Environment by Live-cell Photoaffinity Labeling
Published on: September 20, 2016
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
01:10Pharmacokinetics: Overview
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
01:13Bioavailability: Overview
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
01:17Bioavailability: Overview
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...